Ligand ID: H8J Drugbank ID: DB00247(Methysergide) Indication:For the treatment of vascular headache |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 1q2w | 3C-LIKE PROTEASE (SARSr-CoV) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.59A | 20.09 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 1qz8 | POLYPROTEIN 1AB (SARSr-CoV) | 6 / 12 | VAL A 102SER A 105LEU A 88PHE A 90GLY B 100VAL A 110 | 1.64A | 14.99 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 1z1j | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL B1042THR B1025LEU B1089PHE B1066GLY B1023VAL B1018 | 1.46A | 20.73 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 2amd | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.54A | 20.96 | None9IN A1001 (-4.0A)NoneNoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 2dd8 | IGG HEAVY CHAIN (Homosapiens) | 5 / 12 | VAL H 207THR H 205VAL H 211GLY H 118VAL H 152 | 1.06A | 19.70 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 2op9 | REPLICASEPOLYPROTEIN 1AB(PP1AB, ORF1AB)3C-LIKE PROTEINASE(3CL-PRO, 3CLP) (SARSr-CoV) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.62A | 21.14 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 2q6g | REPLICASEPOLYPROTEIN 1AB (SARS-COVBJ01) | 5 / 12 | VAL A 42THR A 25LEU A 89GLY A 23VAL A 18 | 1.21A | 20.49 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 3aw1 | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.56A | 20.73 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 3ea7 | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.58A | 20.05 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 3eaj | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.53A | 20.05 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 3f9f | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL B 42THR B 25LEU B 89PHE B 66GLY B 23VAL B 18 | 1.57A | 21.12 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 3f9g | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.61A | 21.80 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | VAL B 42THR B 25LEU B 89PHE B 66GLY B 23 | 1.19A | 20.49 | None010 F 6 (-3.1A)NoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 3m3s | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL B 42THR B 25LEU B 89PHE B 66GLY B 23VAL B 18 | 1.67A | 20.20 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 3m3v | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | VAL A 42THR A 25LEU A 89GLY A 23VAL A 18 | 1.23A | 20.67 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 3sna | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.64A | 21.19 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 5b6o | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.58A | 20.75 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 6 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23VAL A 18 | 1.65A | 17.04 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 13VAL A 35LEU A 32PHE A 159VAL A 18 | 1.77A | 17.04 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.57A | 17.04 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 148VAL A 35LEU A 32PHE A 159VAL A 86 | 1.78A | 17.04 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 13SER A 10VAL A 36LEU A 30PHE A 159 | 1.70A | 17.04 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 13SER A 10VAL A 18LEU A 30PHE A 159 | 1.80A | 17.04 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 5x5c | S PROTEIN (MERS-CoV) | 6 / 12 | VAL C1124SER C1125LEU C 871PHE C1001GLY C1140VAL C1128 | 1.50A | 16.07 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ack | SPIKE GLYCOPROTEIN (SARSr-CoV) | 6 / 12 | VAL B 498LEU B 499PHE B 325GLY B 512PHE B 379VAL B 369 | 1.63A | 17.89 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6crx | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 6 / 12 | THR C 236VAL C 80PHE C 76PHE C 22ASN C 135TYR C 252 | 1.77A | 17.75 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.67A | 21.97 | NoneNoneNoneNoneNoneDMS A 403 ( 4.9A) | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 6 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23VAL A 18 | 1.70A | 21.97 | NoneNoneNoneNoneNoneDMS A 403 ( 4.9A) | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 6 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23VAL A 18 | 1.71A | 21.89 | NoneNoneNoneNoneNoneDMS A 401 ( 4.8A) | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.65A | 21.89 | NoneNoneNoneNoneNoneDMS A 401 ( 4.8A) | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 6 / 12 | VAL C 42THR C 25LEU C 89PHE C 66GLY C 23VAL C 18 | 1.60A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 6 / 12 | VAL B 42THR B 25LEU B 89PHE B 66GLY B 23VAL B 18 | 1.61A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 87GLY A 23VAL A 18 | 1.57A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89GLY A 23VAL A 18 | 1.55A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89GLY A 23VAL A 18 | 1.44A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 6 / 12 | VAL D 42THR D 25LEU D 89PHE D 66GLY D 23VAL D 18 | 1.46A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 6 / 12 | THR D 25VAL D 35LEU D 89PHE D 66GLY D 23VAL D 18 | 1.55A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 6 / 12 | THR B 25VAL B 35LEU B 89PHE B 66GLY B 23VAL B 18 | 1.66A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 6 / 12 | THR C 25VAL C 35LEU C 89PHE C 66GLY C 23VAL C 18 | 1.66A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 42LEU A 89PHE A 66GLY A 23VAL A 18 | 1.66A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.58A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 6 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23VAL A 18 | 1.67A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m71 | NSP12 (SARS-CoV-2) | 6 / 12 | SER A 709THR A 710VAL A 472GLY A 774ASN A 703VAL A 785 | 1.79A | 18.58 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 709THR A 710VAL A 31GLY A 712TYR A 129 | 1.57A | 18.58 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 709THR A 710GLY A 712PHE A 48TYR A 129 | 1.56A | 18.58 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 764SER A 754PHE A 782ASN A 695VAL A 588 | 1.66A | 18.58 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6nb8 | S230 ANTIGEN-BINDING(FAB) FRAGMENT,HEAVY CHAIN (Homosapiens) | 5 / 12 | VAL H 221THR H 219VAL H 225GLY H 132VAL H 166 | 1.06A | 18.93 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6vww | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 6 / 12 | THR A 145VAL A 183PHE A 135GLY A 126PHE A 123TYR A 325 | 1.77A | 22.57 | GOL A 402 (-4.2A)NoneNoneGOL A 402 (-3.8A)NoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w41 | CR3022 FAB HEAVYCHAINCR3022 FAB LIGHTCHAIN (Homosapiens) | 5 / 12 | VAL H 182THR H 183VAL H 198PHE L 118VAL H 211 | 1.66A | 17.24 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w41 | CR3022 FAB HEAVYCHAINSPIKE PROTEIN S1 (Homosapiens;SARS-CoV-2) | 5 / 12 | SER H 96THR H 100VAL C 367GLY C 381PHE C 377 | 1.72A | 17.24 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 5 / 12 | VAL C 367LEU C 368PHE C 377GLY C 431PHE C 515 | 1.80A | 17.94 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w41 | CR3022 FAB HEAVYCHAIN (Homosapiens) | 5 / 12 | VAL H 207THR H 205VAL H 211GLY H 118VAL H 152 | 1.01A | 17.24 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 5 / 12 | SER C 514THR C 430VAL C 407GLY C 381VAL C 511 | 1.69A | 17.94 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w41 | CR3022 FAB HEAVYCHAINCR3022 FAB LIGHTCHAIN (Homosapiens) | 5 / 12 | VAL L 163LEU L 136PHE L 139ASN L 137VAL H 181 | 1.65A | 16.99 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w41 | CR3022 FAB HEAVYCHAIN (Homosapiens) | 5 / 12 | VAL H 184THR H 183GLY H 162ASN H 155VAL H 211 | 1.68A | 17.24 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w4b | NSP9 (SARS-CoV-2) | 6 / 12 | VAL A 103SER A 106LEU A 89PHE A 91GLY B 101VAL A 111 | 1.59A | 16.16 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89GLY A 23VAL A 18 | 1.42A | 21.76 | NoneX77 A 401 (-4.2A)NoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23 | 1.64A | 21.76 | X77 A 401 (-4.2A)NoneNoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23 | 1.47A | 21.76 | NoneX77 A 401 (-4.2A)NoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 87GLY A 23VAL A 18 | 1.54A | 21.76 | NoneX77 A 401 (-4.2A)NoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89GLY A 23VAL A 18 | 1.53A | 21.76 | X77 A 401 (-4.2A)NoneNoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 36VAL A 24LEU A 53GLY A 97VAL A 155 | 1.75A | 17.11 | NoneNoneNoneNoneAMP A 201 ( 4.4A) | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 95SER A 80VAL A 121LEU A 122ASN A 117 | 1.67A | 17.11 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | VAL B 95SER B 80VAL B 121LEU B 122ASN B 117 | 1.69A | 17.11 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | SER B 170THR B 168PHE B 127PHE B 241VAL B 205 | 1.64A | 20.38 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 5 / 12 | VAL A 102SER A 105LEU A 88PHE A 90VAL A 110 | 1.59A | 18.06 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 95SER A 80VAL A 121LEU A 122ASN A 117 | 1.66A | 16.09 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 299SER A 284VAL A 325LEU A 326ASN A 321 | 1.65A | 17.19 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wiq | NSP7 (SARS-CoV-2) | 5 / 12 | VAL A 58SER A 61VAL A 12LEU A 13VAL A 66 | 1.54A | 11.71 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 6 / 12 | THR A 145VAL A 183PHE A 135GLY A 126PHE A 123TYR A 325 | 1.79A | 22.37 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 6 / 12 | THR B 145VAL B 183PHE B 135GLY B 126PHE B 123TYR B 325 | 1.79A | 22.37 | ACT B 408 (-4.0A)NoneNoneACT B 408 (-4.2A)NoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.60A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 6 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23VAL A 18 | 1.67A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wqd | NSP7 (SARS-CoV-2) | 5 / 12 | VAL A 58SER A 61VAL A 12LEU A 13VAL A 66 | 1.53A | 11.71 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wqd | NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 58SER C 61VAL C 12LEU C 13VAL C 66 | 1.46A | 11.71 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23 | 1.45A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 87GLY A 23VAL A 18 | 1.56A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89GLY A 23VAL A 18 | 1.39A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23 | 1.63A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89GLY A 23VAL A 18 | 1.49A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | THR A 210VAL A 184LEU A 185GLY A 209VAL A 205 | 1.64A | 20.19 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6y2g | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 6 / 12 | VAL B 42THR B 25LEU B 89PHE B 66GLY B 23VAL B 18 | 1.54A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23 | 1.42A | 17.28 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89GLY A 23VAL A 18 | 1.40A | 17.28 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 13SER A 10VAL A 36LEU A 30PHE A 159 | 1.70A | 17.28 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23 | 1.62A | 17.28 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 87GLY A 23VAL A 18 | 1.53A | 17.28 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 13VAL A 35LEU A 32PHE A 159VAL A 18 | 1.78A | 17.28 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 148VAL A 35LEU A 32PHE A 159VAL A 86 | 1.78A | 17.28 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89GLY A 23VAL A 18 | 1.51A | 17.28 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 13SER A 10VAL A 18LEU A 30PHE A 159 | 1.80A | 17.28 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | VAL C 58SER C 61VAL C 12LEU C 13VAL C 66 | 1.52A | 11.00 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | VAL A 58SER A 61VAL A 12LEU A 13VAL A 66 | 1.53A | 11.00 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL A 512LEU A 513PHE A 338GLY A 526VAL A 382 | 1.40A | 18.54 | NoneNoneNoneNoneDMS A 905 (-4.3A) | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | VAL H 211THR H 209VAL H 215GLY H 122VAL H 156 | 1.17A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | LIGHT CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 5 / 12 | THR E 430LEU E 390PHE E 392GLY E 431TYR L 97 | 1.43A | 18.54 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | LIGHT CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 5 / 12 | THR A 430LEU A 390PHE A 392GLY A 431TYR C 97 | 1.36A | 18.54 | NoneDMS A 905 (-4.9A)NoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | VAL H 186THR H 187VAL H 202PHE L 124VAL H 215 | 1.64A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | VAL H 188THR H 187GLY H 166ASN H 159VAL H 215 | 1.66A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | VAL B 211THR B 209VAL B 215GLY B 122VAL B 156 | 1.15A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | VAL B 186THR B 187VAL B 202PHE C 124VAL B 215 | 1.62A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | VAL L 169LEU L 142PHE L 145ASN L 143VAL H 185 | 1.65A | 19.23 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 512LEU E 513PHE E 338GLY E 526VAL E 382 | 1.42A | 18.54 | NoneNoneNoneNoneDMS L1601 (-4.2A) | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ym0 | LIGHT CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 5 / 12 | THR E 430LEU E 390PHE E 392GLY E 431TYR L 97 | 1.36A | 18.54 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ym0 | HEAVY CHAIN (Homosapiens) | 5 / 12 | VAL H 211THR H 209VAL H 215GLY H 122VAL H 156 | 1.12A | 17.27 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 512LEU E 513PHE E 338GLY E 526VAL E 382 | 1.41A | 18.54 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ym0 | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | VAL H 186THR H 187VAL H 202PHE L 124VAL H 215 | 1.63A | 17.27 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 87GLY A 23VAL A 18 | 1.66A | 22.25 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89GLY A 23VAL A 18 | 1.66A | 22.25 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89GLY A 23VAL A 18 | 1.58A | 22.25 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 13SER A 10VAL A 36LEU A 30PHE A 159 | 1.65A | 22.25 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | VAL H 188THR H 187GLY H 166ASN H 159VAL H 215 | 1.66A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | IGG H CHAINIGG L CHAIN (Homosapiens) | 5 / 12 | VAL H 186THR H 187VAL H 202PHE L 124VAL H 215 | 1.64A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | IGG H CHAINIGG L CHAIN (Homosapiens) | 5 / 12 | VAL B 186THR B 187VAL B 202PHE C 124VAL B 215 | 1.65A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | IGG H CHAINIGG L CHAIN (Homosapiens) | 5 / 12 | VAL C 169LEU C 142PHE C 145ASN C 143VAL B 185 | 1.65A | 19.23 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | IGG H CHAINIGG L CHAIN (Homosapiens) | 5 / 12 | VAL L 169LEU L 142PHE L 145ASN L 143VAL H 185 | 1.64A | 19.23 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 512LEU E 513PHE E 338GLY E 526VAL E 382 | 1.42A | 17.75 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | VAL B 211THR B 209VAL B 215GLY B 122VAL B 156 | 1.17A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | IGG L CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 5 / 12 | THR A 430LEU A 390PHE A 392GLY A 431TYR C 97 | 1.44A | 17.75 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL A 512LEU A 513PHE A 338GLY A 526VAL A 382 | 1.41A | 17.75 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | VAL H 211THR H 209VAL H 215GLY H 122VAL H 156 | 1.17A | 17.52 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yor | IGG L CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 5 / 12 | THR E 430LEU E 390PHE E 392GLY E 431TYR L 97 | 1.43A | 17.75 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89GLY A 23VAL A 18 | 1.53A | 22.25 | PK8 A 401 ( 4.4A)NoneNoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 87GLY A 23VAL A 18 | 1.53A | 22.25 | NonePK8 A 401 ( 4.4A)NoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23 | 1.43A | 22.25 | NonePK8 A 401 ( 4.4A)NoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23 | 1.63A | 22.25 | PK8 A 401 ( 4.4A)NoneNoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 42THR A 25LEU A 89GLY A 23VAL A 18 | 1.42A | 22.25 | NonePK8 A 401 ( 4.4A)NoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL C 95SER C 80VAL C 121LEU C 122ASN C 117 | 1.64A | 17.32 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL E 95SER E 80VAL E 121LEU E 122ASN E 117 | 1.65A | 17.32 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL B 95SER B 80VAL B 121LEU B 122ASN B 117 | 1.63A | 17.32 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL D 95SER D 80VAL D 121LEU D 122ASN D 117 | 1.64A | 17.32 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL A 95SER A 80VAL A 121LEU A 122ASN A 117 | 1.65A | 17.32 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL B 95SER B 80VAL B 121LEU B 122ASN B 117 | 1.65A | 17.32 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL D 95SER D 80VAL D 121LEU D 122ASN D 117 | 1.65A | 17.32 | NoneEDO D 203 (-3.6A)NoneNoneNone | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL B 95SER B 80VAL B 121LEU B 122ASN B 117 | 1.64A | 17.32 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.57A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 6 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23VAL A 18 | 1.64A | 21.76 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 588THR A 591VAL A 764PHE A 812GLY A 597 | 1.64A | 18.58 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 709THR A 710GLY A 712PHE A 48TYR A 129 | 1.50A | 18.58 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7btf | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | SER C 61VAL C 12LEU D 91PHE D 92GLY C 64 | 1.52A | 11.71 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 709THR A 710VAL A 31GLY A 712TYR A 129 | 1.61A | 18.58 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 6 / 12 | VAL A 42THR A 25LEU A 89PHE A 66GLY A 23VAL A 18 | 1.64A | 21.76 | NoneNoneNoneNoneNoneDMS A 403 ( 4.9A) | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 6 / 12 | THR A 25VAL A 35LEU A 89PHE A 66GLY A 23VAL A 18 | 1.71A | 21.76 | NoneNoneNoneNoneNoneDMS A 403 ( 4.9A) | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 709THR A 710VAL A 31GLY A 712TYR A 129 | 1.48A | 18.61 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 588THR A 591VAL A 764PHE A 812GLY A 597 | 1.65A | 18.61 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 709THR A 710GLY A 712PHE A 48TYR A 129 | 1.32A | 18.61 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | VAL A 335SER A 363LEU B 95PHE B 92VAL A 342 | 1.50A | 18.61 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 588THR A 591VAL A 764PHE A 812GLY A 597 | 1.63A | 18.61 | None | ||
![]() | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 709THR A 710GLY A 712PHE A 48TYR A 129 | 1.54A | 18.61 | None |